CTOs on the Move

Oyster Point Pharma

www.oysterpointrx.com

 
Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Oyster Point Pharma raised $93M on 02/26/2019

Similar Companies

Dynarex Corporation

Dynarex Corporation is a Orangeburg, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow`s pipeline is led by SPI-62 in Phase 2 clinical development.

Infinity Care Solutions

Infinity Care Solutions wants to take the time and trouble out of a normal pharmacy experience by not only providing you with traditional medications, but also offering you and your healthcare provider a choice. We know that no two patients are exactly the same and each requires specific knowledge and a team approach. It is our goal to meet this challenge head on. With our top-of-the-line, custom-made compounded products, and our impeccable customer service, our mission is for you to experience symptom relief like never before. Our pharmacy is built on a solid foundation of medical expertise and cutting edge pharmaceutical compounding methods that are unmatched, especially in the areas of topical hormone replacement therapy and topical pain medications.

Allegro Ophthalmics

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.